COCP - コクリスタル・ファ―マ (Cocrystal Pharma Inc.) コクリスタル・ファ―マ

 COCPのチャート


 COCPの企業情報

symbol COCP
会社名 Cocrystal Pharma Inc (コクリスタル・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Cocrystal Pharma Inc. is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.   コクリスタル・ファ―マは米国の医薬品企業。主にヒトのウィルス性疾患の治療薬の開発に従事する。ウィルスの複製機能を阻害する抗ウィルス治療薬で、RNAポリメラ―ゼ酵素、ヘリカ―ゼ酵素、C型肝炎のNS5Aたんぱく質、インフルエンザウィルスやノロウィルスのRNAポリメラ―ゼを含む。同社は薬物レベルでの酵素相互作用に焦点を当てる。本社はジョ―ジア州タッカ―。   Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
本社所在地 1860 Montreal Road Tucker GA 30084 USA
代表者氏名 Raymond F. Schinazi レイモンドF.シナジー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 425-398-7178
設立年月日 39052
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 10人
url https://www.cocrystalpharma.com/
nasdaq_url https://www.nasdaq.com/symbol/cocp
adr_tso
EBITDA EBITDA(百万ドル) -8.06300
終値(lastsale) 2.725
時価総額(marketcap) 81540382.1
時価総額 時価総額(百万ドル) 81.98923
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 75.14823
当期純利益 当期純利益(百万ドル) 0.04100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cocrystal Pharma Inc revenues was not reported. Net loss decreased 18% to $2.9M. Lower net loss reflects Research and development decrease of 40% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.11.

 COCPのテクニカル分析


 COCPのニュース

   Cocrystal Pharma GAAP EPS of -$0.70 misses by $0.21  2022/11/14 13:48:40 Seeking Alpha
Cocrystal Pharma press release (COCP): Q3 GAAP EPS of -$0.70 misses by $0.21.Cocrystal reported unrestricted cash of $42.1 million as of September 30, 2022 compared with $58.7 million…
   Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs  2022/11/14 13:00:00 GlobeNewswire
BOTHELL, Wash., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three and nine months ended September 30, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
   Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday  2022/11/03 09:40:43 Benzinga
Gainers Starry Group Holdings, Inc. (NYSE: STRY ) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. Benefitfocus, Inc. (NASDAQ: BNFT ) shares surged 48.2% to settle at $10.36 on Wednesday after the company announced it will be acquired by Voya Financial for $10.50 per share. Forza X1, Inc. (NASDAQ: FRZA ) climbed 45% to close at $2.45 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ: BAND ) rose 41.6% to close at $17.42 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Rayonier Advanced Materials Inc. (NYSE: RYAM ) shares gained 34.2% to close at $6.00 as the company posted upbeat quarterly results. Chegg, Inc. (NYSE: CHGG ) gained 22% to close at $25.75 after the company reported better-than-expected Q3 results. The company also issued FY22 sales guidance above analyst estimates.
   Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday''s Mid-Day Session  2022/11/02 17:28:02 Benzinga
Gainers Starry Group Holdings, Inc. (NYSE: STRY ) gained 56% to $0.2808 after reporting Q3 results. Benefitfocus, Inc. (NASDAQ: BNFT ) shares jumped 47.8% to $10.33 after the company announced it will be acquired by Voya Financial for $10.50 per share. Akso Health Group (NASDAQ: AHG ) gained 44% to $0.7280. Rayonier Advanced Materials Inc. (NYSE: RYAM ) shares climbed 40.9% to $6.30 as the company posted upbeat quarterly results. Forza X1, Inc. (NASDAQ: FRZA ) jumped 39% to $2.3495 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ: BAND ) gained 36.9% to $16.84 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) shares rose 32.8% to $24.30 after the company announced collaboration with CSL to develop and commercialize self-amplifying mRNA vaccines.
   Cocrystal Pharma to Participate in Two Investor Conferences in November  2022/11/02 12:00:00 GlobeNewswire
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows:
   Cocrystal Pharma completes single ascending dose of phase 1 study of influenza A drug  2022/07/14 13:15:21 Seeking Alpha
Cocrystal Pharma (COCP) stock has risen 5.4% premarket after it said the single ascending dose portion of the Phase 1 study with its orally administered antiviral candidate CC-42344…
   Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors  2022/06/01 12:00:00 Cocrystal Pharma
We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
   Companies - Cocrystal Pharma, Inc. Sees Large Decline in Short Interest  2022/05/27 19:01:09 Business Mag
Cocrystal Pharma, Inc. was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 58,200 shares, a decline…
   Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference  2022/05/18 12:00:00 GlobeNewswire
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.
   Volume - Cocrystal Pharma, Inc. Sees Significant Drop in Short Interest  2022/05/16 16:21:10 Business Mag
Cocrystal Pharma, Inc. was the target of a large decrease in short interest in April. As of April 30th, there was short interest totalling 139,900 shares, a decrease of 23.8%…
   Cocrystal Pharma completes single ascending dose of phase 1 study of influenza A drug  2022/07/14 13:15:21 Seeking Alpha
Cocrystal Pharma (COCP) stock has risen 5.4% premarket after it said the single ascending dose portion of the Phase 1 study with its orally administered antiviral candidate CC-42344…
   Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors  2022/06/01 12:00:00 Cocrystal Pharma
We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
   Companies - Cocrystal Pharma, Inc. Sees Large Decline in Short Interest  2022/05/27 19:01:09 Business Mag
Cocrystal Pharma, Inc. was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 58,200 shares, a decline…
   Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference  2022/05/18 12:00:00 GlobeNewswire
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.
   Volume - Cocrystal Pharma, Inc. Sees Significant Drop in Short Interest  2022/05/16 16:21:10 Business Mag
Cocrystal Pharma, Inc. was the target of a large decrease in short interest in April. As of April 30th, there was short interest totalling 139,900 shares, a decrease of 23.8%…

 関連キーワード  (医薬品 米国株 コクリスタル・ファ―マ COCP Cocrystal Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)